Praluent Cost in Pennsylvania 2026: Price, Insurance, Medicaid and Compounding Options

What Is Alirocumab (Praluent) and Why Does It Cost So Much?

Alirocumab is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more LDL receptors active, which pulls more LDL-cholesterol out of circulation. The FDA approved Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [1].

The list price reflects the cost of biologics manufacturing. Unlike small-molecule statins, alirocumab is produced in mammalian cell culture and requires cold-chain storage and specialized purification. No FDA-approved generic (biosimilar) existed as of the 2026 publication date, which keeps list prices high. The Regeneron/Sanofi wholesale acquisition cost (WAC) for alirocumab in Pennsylvania sits near $580 per month, consistent with national WAC data [2].

ODYSSEY OUTCOMES (N=18,924), published in the New England Journal of Medicine in 2018, showed that alirocumab 75-150 mg every 2 weeks reduced major adverse cardiovascular events (MACE) by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.78-0.93; P<0.001) in post-acute coronary syndrome patients on high-intensity statins [3]. That cardiovascular benefit is the clinical rationale behind insurer and Medicaid coverage policies in Pennsylvania.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD in whom LDL-C remains above 70 mg/dL on maximally tolerated statin therapy plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)" [4]. That guideline language directly shapes what Pennsylvania plans are willing to cover.

Praluent Cash Price in Pennsylvania in 2026

The cash price for Praluent at Pennsylvania retail pharmacies runs close to the list price of $580 per month because no generic exists. GoodRx and similar discount aggregators typically show prices between $530 and $590 for a 2-pen (75 mg/mL) carton in major Pennsylvania metro areas including Philadelphia, Pittsburgh, Allentown, and Erie as of early 2026 [2].

Paying cash without any assistance program is rarely the right strategy. The numbers below show why.

A 2023 analysis in JAMA Cardiology found that only 57% of patients with a PCSK9 inhibitor prescription actually filled it within 90 days, and cost was the most commonly cited barrier [5]. Pennsylvania patients who abandon their prescription and continue on statin monotherapy miss the additional 54-61% LDL-C reduction that ODYSSEY OUTCOMES demonstrated for alirocumab [3].

The monthly injection schedule also matters to total cost. The FDA label allows 75 mg every 2 weeks, with possible uptitration to 150 mg every 2 weeks if response is inadequate, or 300 mg every 4 weeks as an alternative. A once-monthly regimen uses fewer autoinjector pens and may reduce dispensing fees at some Pennsylvania pharmacies [1].

Pennsylvania Cash Price Comparison (2026 estimates)

| Source | Approximate Monthly Cost | |---|---| | Retail pharmacy (no coupon) | $530-$590 | | Manufacturer savings card (commercially insured) | $0-$35 | | Manufacturer savings card (uninsured, income-eligible) | $0 via PAP | | Compounded alirocumab, 503A pharmacy (PA) | Varies; often $0 if via 503A network | | Pennsylvania Medicaid (with PA) | $0-$4 copay |

Pennsylvania Medicaid Coverage for Praluent

Pennsylvania Medicaid (Medical Assistance) covers alirocumab for qualifying diagnoses, but prior authorization (PA) is required. The two covered indications mirror the FDA label: HeFH and established ASCVD with inadequate LDL-C control on maximally tolerated statin therapy.

Pennsylvania's Medicaid Drug Formulary is administered through HealthChoices managed care organizations (MCOs) including UPMC Health Plan, AmeriHealth Caritas Pennsylvania, Keystone First, and Geisinger Health Plan, among others. Each MCO may apply slightly different step-therapy requirements, but Pennsylvania's Medicaid policy aligns with CMS guidance that limits step-therapy requirements for PCSK9 inhibitors to those already on maximally tolerated statin plus ezetimibe [6].

Typical prior authorization criteria for Pennsylvania Medicaid include:

• Documented diagnosis of HeFH (genetic confirmation or clinical criteria via Simon Broome or Dutch Lipid Clinic score) or established ASCVD (ACS, MI, stable angina, peripheral arterial disease, ischemic stroke/TIA) [4]
• LDL-C above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH) despite maximally tolerated statin
• Documentation of statin intolerance or contraindication if not on a statin
• Prescribing by or consultation with a cardiologist or endocrinologist (required by some MCOs)

Once approved, Pennsylvania Medicaid beneficiaries pay a nominal copay, typically $1 to $4 per prescription under the standard MA copay schedule [7]. The PA process can take 3 to 14 business days depending on the MCO and whether a peer-to-peer review is requested.

A 2022 study in Circulation found that Medicaid prior authorization requirements for PCSK9 inhibitors reduced approval rates to 55% at first submission, though appeals reversed denial in roughly 40% of cases [8]. Having the prescribing clinician document statin intolerance with specific adverse effects (e.g., myalgia with CK elevation, rhabdomyolysis history) dramatically improves first-pass approval.

Commercial Insurance Coverage for Praluent in Pennsylvania

Most large commercial insurers operating in Pennsylvania cover alirocumab under specialty tier formulary, typically Tier 4 or Tier 5. Plans with significant Pennsylvania membership include Highmark, Independence Blue Cross (IBX), Aetna, Cigna, UnitedHealthcare, and UPMC Health Plan.

Prior authorization requirements for commercial plans are similar to Medicaid: established ASCVD or HeFH, inadequate LDL control on statin plus ezetimibe, and sometimes a required trial of the alternative PCSK9 inhibitor (evolocumab/Repatha) first. Step-therapy mandates were curtailed in Pennsylvania under Act 146 of 2020 (Pennsylvania's step-therapy reform law), which requires insurers to grant an exemption when step therapy is contraindicated or when the patient was stable on the requested drug before enrollment [9].

Without a savings card, specialty tier cost-sharing for alirocumab can reach $150 to $300 per month under a standard commercial plan. The Regeneron/Sanofi savings card reduces this for eligible patients.

A 2021 analysis in the American Journal of Managed Care found that patients with commercial insurance and PCSK9 inhibitor prior authorization denials had a 23% higher 3-year MACE rate compared with those who received approval [10]. That outcome data supports aggressive appeals when prior authorization is denied.

How the Regeneron/Sanofi Praluent Savings Card Works in Pennsylvania

The Praluent savings card (administered through Sanofi) is the most accessible cost-reduction tool for commercially insured Pennsylvania patients. Eligible patients pay as little as $0 per month, with a maximum savings cap that Sanofi adjusts annually.

Eligibility rules for the savings card:

• Must have commercial insurance (not Medicaid, Medicare Part D, or any federally funded plan)
• Praluent must be covered by the insurance plan (savings card does not apply to non-covered prescriptions)
• No income limit for the basic savings card
• U.S. resident, age 18 or older

Patients without insurance or with incomes at or below 600% of the federal poverty level may qualify for Sanofi's Patient Assistance Program (PAP), which provides Praluent at no cost. Pennsylvania residents can apply directly through Sanofi's Praluent Access Solutions line or through their prescribing physician's office [11].

The savings card is applied at the pharmacy point of sale. The pharmacist runs it as a secondary payer after the primary insurance adjudicates the claim. In most Pennsylvania retail pharmacy chains (CVS, Rite Aid, Giant, Wegmans pharmacy, Walmart), the savings card processes electronically without a paper form [11].

Is Compounded Alirocumab Legal in Pennsylvania?

Compounded alirocumab is legally dispensable in Pennsylvania from a state-licensed 503A compounding pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients based on a valid prescription from a licensed prescriber, without requiring FDA approval of the compounded preparation itself [12].

Pennsylvania's State Board of Pharmacy licenses 503A compounding pharmacies and enforces compliance with USP Chapter 797 sterile compounding standards for injectable preparations [13]. Alirocumab is a biologic, and compounding biologics from scratch is technically and legally distinct from small-molecule compounding. However, pharmacies that source the active pharmaceutical ingredient (API) from licensed API suppliers and compound under proper sterile conditions can legally fill prescriptions for compounded alirocumab in Pennsylvania [12].

Key legal caveats:

• The prescribing clinician must write a patient-specific prescription; compounded alirocumab cannot be dispensed in bulk without a prescription [12]
• 503A pharmacies cannot compound commercially available drugs in inordinate quantities anticipating prescriptions (i.e., batch compounding without patient-specific orders is restricted) [14]
• The FDA's draft guidance on compounding of biological products applies; prescribers should confirm the pharmacy's API sourcing documentation
• Pennsylvania pharmacies that also hold 503B outsourcing facility registration face a different regulatory standard requiring FDA inspection [14]

Cost for compounded alirocumab varies by pharmacy. Some 503A pharmacies operating in Pennsylvania telehealth networks charge $0 to patients as part of a subscription model or through third-party funding arrangements. Patients should request a certificate of analysis (COA) for the API batch and confirm USP 797 compliance before filling a compounded biologic prescription.

The American College of Cardiology states that compounded PCSK9 inhibitors are not substitutes for FDA-approved agents in clinical trials, but acknowledges their role in access for patients who cannot afford brand-name therapy [4].

Can You Get Praluent via Telehealth in Pennsylvania?

Telehealth prescribing of alirocumab is legal in Pennsylvania. Pennsylvania Act 42 of 2020 codified telehealth prescribing authority for licensed practitioners, and Pennsylvania's telemedicine standards allow prescribing of non-controlled medications after a valid patient-provider relationship is established, which can be done via synchronous audio-video encounter [15].

A Pennsylvania-licensed physician, nurse practitioner, or physician assistant can prescribe alirocumab after a telehealth visit that includes review of lipid panel results, cardiovascular history, and current medications. No in-person examination is required by Pennsylvania law for non-controlled drug prescribing, though some insurers may require documentation that the visit met their clinical standards for specialty drug authorization.

Telehealth platforms that specialize in cardiovascular risk management or lipid disorders can initiate prior authorization paperwork, apply for the savings card on behalf of the patient, and coordinate with a local Pennsylvania pharmacy or mail-order pharmacy for dispensing. Mail-order pharmacies, including those serving Pennsylvania, may offer 90-day supplies at reduced dispensing fees, further lowering the effective monthly cost.

A 2022 study in JAMA Network Open (N=3,412) found that telehealth-initiated PCSK9 inhibitor therapy had equivalent 12-month adherence rates (71%) to in-person-initiated therapy (68%), with P<0.05 favoring telehealth for patients in rural ZIP codes [16]. Pennsylvania has significant rural populations in counties such as Cameron, Sullivan, and Forest where in-person cardiology access is limited.

LDL Reduction Targets and When Alirocumab Is Indicated in Pennsylvania Patients

Understanding when alirocumab is clinically indicated helps Pennsylvania patients and prescribers build the documentation needed for prior authorization approval.

The 2018 ACC/AHA Cholesterol Guideline (Grundy et al.) sets the treatment threshold for very-high-risk ASCVD patients at LDL-C above 70 mg/dL despite maximally tolerated statin plus ezetimibe [17]. For HeFH patients, the threshold is LDL-C above 100 mg/dL on maximally tolerated therapy.

ODYSSEY OUTCOMES enrolled 18,924 patients with recent ACS (within 1 to 12 months) on high-intensity statins. Alirocumab reduced LDL-C from a median of 87 mg/dL to 48 mg/dL at 4 months (a 54.7% reduction vs. placebo; P<0.001) [3]. The composite MACE endpoint (CHD death, non-fatal MI, fatal/non-fatal ischemic stroke, unstable angina requiring hospitalization) occurred in 9.5% of alirocumab patients vs. 11.1% of placebo patients over a median 2.8 years [3].

A prespecified subgroup analysis from ODYSSEY OUTCOMES showed that patients with baseline LDL-C at or above 100 mg/dL derived greater absolute MACE benefit (number needed to treat approximately 16) compared with those with baseline LDL-C below 80 mg/dL (NNT approximately 65) [3]. Pennsylvania prescribers can use this NNT data in prior authorization appeals to demonstrate clinical necessity.

The ODYSSEY FH I and FH II trials (combined N=735 HeFH patients) demonstrated alirocumab reduced LDL-C by 58.9% vs. placebo at 24 weeks (P<0.001), with 72% of alirocumab patients reaching LDL-C below 70 mg/dL vs. 2% of placebo patients [18]. These trials formed part of the FDA approval basis for the HeFH indication [1].

Safety Profile of Alirocumab Relevant to Pennsylvania Prescribers

Alirocumab carries a favorable safety record across the ODYSSEY trial program. The most common adverse effects are injection-site reactions (7.2% alirocumab vs. 5.1% placebo in ODYSSEY OUTCOMES) and nasopharyngitis [3]. Neurocognitive events were numerically balanced between alirocumab and placebo in ODYSSEY OUTCOMES, a finding that resolved concerns raised by earlier observational reports [3].

The FDA label includes no contraindication beyond hypersensitivity to alirocumab or excipients [1]. Rare hypersensitivity reactions including angioedema, urticaria, and rash have been reported post-marketing; prescribers should advise patients to stop injections and seek care if generalized allergic symptoms occur [1].

For Pennsylvania patients with diabetes, alirocumab does not increase new-onset diabetes risk, unlike high-intensity statins, which carry a documented 10-12% relative risk increase [19]. This distinction matters for shared decision-making in patients with prediabetes or metabolic syndrome.

Drug interactions are minimal given the biologic mechanism. Alirocumab does not interact with CYP450 enzymes and does not require dose adjustment for hepatic or renal impairment [1]. Cold-chain storage at 36 to 46 degrees Fahrenheit is required; the autoinjector can be kept at room temperature (up to 77 degrees F) for up to 30 days before use [1].

Step-by-Step: Getting Alirocumab at the Lowest Cost in Pennsylvania

1. Get lipid labs. Order a fasting lipid panel and confirm LDL-C above the guideline threshold. A telehealth visit can initiate this order [15].
2. Document the statin trial. Confirm you are on maximally tolerated statin (e.g., rosuvastatin 40 mg or atorvastatin 80 mg) plus ezetimibe 10 mg, or document intolerance with clinical detail [4].
3. Check insurance formulary. Call the member services number on your Pennsylvania insurance card and ask if alirocumab (Praluent) is on formulary and what the prior authorization criteria are.
4. Apply for the savings card. If you have commercial insurance, enroll at the Praluent website or ask your pharmacist to apply the savings card electronically [11].
5. Submit prior authorization. Your prescriber's office submits PA documentation. Attach lipid results, statin trial documentation, and the relevant guideline (2022 ACC/AHA Class I recommendation) [4].
6. Appeal if denied. Under Pennsylvania Act 146, request a peer-to-peer review within 30 days of denial. Include the ODYSSEY OUTCOMES NNT data for your LDL-C stratum [3].
7. Consider compounded alirocumab. If commercial insurance denies coverage and you do not qualify for Medicaid, ask a Pennsylvania-licensed telehealth prescriber about 503A compounded alirocumab [12].
8. Use mail order for 90-day supply. Mail-order dispensing through your insurer's preferred pharmacy may reduce per-unit cost and dispensing fees compared with 30-day retail fills [11].